Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma

PARP inhibitors (PARPi) have activity in homologous recombination (HR) repair-deficient, high-grade serous ovarian cancers (HGSOC). However, even responsive tumors develop PARPi resistance, highlighting the need to delay or prevent the appearance of PARPi resistance. Here, we showed that the ALK kin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanakkanthara, Arun, Hou, Xiaonan, Ekstrom, Thomas L., Zanfagnin, Valentina, Huehls, Amelia M., Kelly, Rebecca L., Ding, Husheng, Larson, Melissa C., Vasmatzis, George, Oberg, Ann L., Kaufmann, Scott H., Mansfield, Aaron S., Weroha, S. John, Karnitz, Larry M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770599/
https://www.ncbi.nlm.nih.gov/pubmed/34810199
http://dx.doi.org/10.1158/0008-5472.CAN-21-0732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770599/
https://www.ncbi.nlm.nih.gov/pubmed/34810199
http://dx.doi.org/10.1158/0008-5472.CAN-21-0732

Ejemplares similares